✨ Free AI Report
Medtronic plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Medtronic plc
Company Research

Medtronic plc: Business Overview, Financials & Competitive Analysis

Medtronic plc is the leading global healthcare technology company headquartered in Galway, Ireland, with 95,000+ employees across 150+ countries. The company treats 70 health conditions through cardiac devices, surgic...

Analyst-debate audio for Medtronic plc

AskCyborg analysts argue the bull and bear cases for Medtronic plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Medtronic's combination of steady revenue growth, strategic reinvention, and breakthrough product innovation in high-margin...

Read the full analyst-debate transcript →
Industry Medical Devices & Healthcare Technology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Medtronic plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Medtronic plc Overview

Pro stress-test →

Medtronic plc is the leading global healthcare technology company headquartered in Galway, Ireland, with 95,000+ employees across 150+ countries. The company treats 70 health conditions through cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems, transforming lives of two people every second worldwide.

Strategic Profile

Pro stress-test →

The company is experiencing its strongest cardiovascular revenue growth in over a decade, with Cardiac Ablation Solutions revenue increasing 71% on the strength of its pulsed field ablation (PFA) portfolio. Medtronic is close to earning clearance for its Hugo system, a robotic-assisted surgery device, which could help maintain the stock's momentum into 2026. The company is spinning off its diabetes care unit, a strategic move expected to be beneficial as the business has weak margins and faces intense competition.

Competitive Landscape

Pro stress-test →

While Medtronic still faces stiff competition in the PFA and Robotics arenas, its diversified portfolio provides a floor that many pure-play competitors lack. In surgical robotics, Medtronic now competes directly with incumbents like Intuitive Surgical in the high-growth soft tissue surgical robotics market. In diabetes care, Medtronic faces competition from Abbott Laboratories' FreeStyle Libre, DexCom's G7, and Tandem Diabetes Care in insulin pumps.

Industry Context

Medtronic plc operates in Medical Devices & Healthcare Technology.

Key facts

Headquarters: Galway, Ireland · Employees: 95000 · Revenue: $34.76B (TTM)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Medtronic plc.

  • Medtronic delivered above-guidance revenue and EPS driven by strong growth in cardiac ablation with accelerated share gains in its PFA franchise, and raised full-year revenue and EPS guidance citing broad-based procedure volume strength.
  • Management emphasized upcoming contributions from new product launches such as Simplicity for hypertension and Altaviva for incontinence, as well as the expansion of the HUGO robotics platform and innovative diabetes sensors.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Received broad, favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity procedure for treatment of uncontrolled hypertension.
  • November 2025Q2 FY26 revenue of $9.0 billion, up 6.6% as reported with adjusted EPS of $1.36 up 8%, leading company to raise FY26 guidance.
  • +1 moreTrack every material event for Medtronic plc as it happens. Explore monitoring →
Get alerted when Medtronic plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

da VinciRobotic-assisted surgical systems→FreeStyle LibreContinuous glucose monitoring systems→G7Continuous glucose monitoring→Johnson & Johnson Cardiac DevicesCardiac devices and ablation solutions→

Compare Medtronic plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Medtronic plc operates in Medical Devices & Healthcare Technology. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices & Healthcare Technology research →
NEW · MCP server

Ask your AI assistant about Medtronic plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Medtronic plc and its top competitor on Cyborg Score”
“What did Medtronic plc do this quarter?”
“Is Medtronic plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Medtronic plc do?+
Medtronic plc is the leading global healthcare technology company headquartered in Galway, Ireland, with 95,000+ employees across 150+ countries. The company treats 70 health conditions through cardiac devices, surgic...
What is Medtronic plc's Cyborg Score?+
Medtronic plc has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Medtronic plc's main competitors?+
Named competitors include da Vinci, FreeStyle Libre, G7, Johnson & Johnson Cardiac Devices. The full competitive landscape is in the AskCyborg report.
How can I get the full Medtronic plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Medtronic plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Medtronic plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Devices & Healthcare Technology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Koninklijke Philips N.V.7Smith & Nephew plc7Terumo Corporation